A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
There are 2 parts to this study. The goal of Part 1 of this clinical research study was to find the highest tolerable dose of SL-401 that can be given to patients with AML. This part of the study is now closed. The goal of Part 2 of this study is to learn if the highest dose tested in Part 1 can help to control the disease. The safety of this drug will be studied in both parts of the study.
Disease Group: Leukemia
Treatment Agent: SL-401
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Stemline Therapeutics, Inc.
IRB Review and Approval Date: 04/07/2015
Recruitment Status: Open
Projected Accrual: 38
Information and next steps
Phase I/Phase II
For general questions about clinical trials: